340B Health

340B reports

New: Addressing the Challenge of Diabetes with 340B Program Savings

Safety-net hospitals use 340B drug pricing program savings to help patients with diabetes afford insulin and to support a wide range of other programs to meet their needs for medical care, education, and disease management. This report provides examples of the direct links between 340B and caring for patients with diabetes. The seven hospital and health system case studies profiled represent a snapshot of the types of diabetes programs that 340B supports and the improved patient health outcomes it achieves. Read the report and see our infographic summarizing the key findings.

2019 340B Health Annual Survey

This year’s 340B Health survey documents the multiple programs and services made possible by the savings the 340B program provides to safety-net and rural hospitals. From offering free and reduced-price medications to medication therapy management to comprehensive oncology programs, 340B hospitals are using 340B savings to meet a wide variety of community needs, especially for vulnerable and rural populations. Without the 340B program, at a minimum, critical programs would need to be scaled back. In some cases, loss of 340B funding could lead to closure. Read the report and see our infographic summarizing the key findings.

340B Program Savings Improve Patient Health Outcomes

Hospitals across the U.S. are using savings from the 340B drug discount program to improve health outcomes for patients living with chronic conditions and reduce overall costs. This report profiles the work of nine hospitals to improve health through a variety of approaches that include help paying for costly drugs, medication management, and assistance with adherence to treatment regimens. Read the report and click here for an infographic summarizing the key findings.

A Comparison of Characteristics of Patients Treated by 340B and Non-340B Providers

340B hospitals provide more care to the nation’s underserved populations compared with non-340B hospitals and private physician offices. Using FY2016 Medicare claims data, researchers at L&M Policy Research find that 340B hospitals treat more patients who are disabled, dually eligible for Medicaid and Medicare, or of certain ethnic/racial minorities. Read the report and click here for an infographic summarizing the findings.

340B Hospitals on the Front Lines of Addressing the U.S. Opioid Epidemic

The United States is currently facing an opioid epidemic that has resulted in more than 700,000 deaths between 1999 and 2017 and cost the economy an estimated $1 trillion since 2001.  As safety-net providers, 340B hospitals have been on the front lines of this issue by establishing targeted programs and services to address the epidemic and prevent further cases of opioid use disorder in their community. This report seeks to better understand the specific role 340B hospitals are playing to address the crisis within their communities, the nature of the programs and services implemented, and how 340B program savings are helping them in their efforts.  Read the report and click here for an infographic summarizing the key findings.

Evaluating the Impact of Raising the DSH Adjustment Percentage Threshold for 340B Program Eligibility on DSH Hospitals and their Low-Income Patients

A recently released Congressional proposal seeks to raise the minimum Medicare disproportionate share (DSH) adjustment percentage required for DSH hospitals to participate in the 340B program from 11.75 percent to 18 percent – a 53 percent increase in the DSH adjustment percentage. Such a change would lead to the termination of 573 DSH hospitals or 51 percent of all DSH hospitals currently enrolled in the program. These hospitals provided roughly $10.8 billion in uncompensated and unreimbursed care in 2016. Losing access to 340B savings would affect the ability of these hospitals to continue providing this high level of care to low-income patients. Nearly 75 percent of states would see 50 percent or more of their DSH hospitals cut from the program, with five states having all of their DSH hospitals cut from the program.  Read the report.

Analysis of 340B Disproportionate Share Hospital Services to Low-Income Patients

A new report shows 340B hospitals provide significantly more care for low-income patients than other hospitals, including uncompensated care and unreimbursed care. They also provide more specialized and community-based health services that are critical for low-income patients but are often underpaid. Read the report and click here for an infographic summarizing the findings.

Medicare Part B Cuts Fact Sheet

This two-pager provides basic facts about the 340B program, how it works, the damage the CMS CY 2018 OPPS final rule would do, and legislation to stop the cuts from taking effect. Click here for a fact sheet.

Medicare Part B Cuts Hurts 340B Hospitals and Patients

The CMS CY 2018 OPPS final rule does not lower drug prices, does not save Medicare money, and does not reduce patients’ drug costs. But it harm hospitals serving low-income communities, forces hospitals to reduce services and layoff staff, and hurts patients. Click here for an infographic.

Assessing the Financial Impact of the 340B Drug Pricing Program on Drug Manufacturers

340B Health commissioned the research firm Dobson DaVanzo & Associates to assess the financial impact of 340B discounts on drug manufacturers and evaluate the plausibility of claims that the 340B Program is a cause of pharmaceutical price increases, cost shifting, and reductions in private sector research and medical discovery. The analysis found that the 340B Program cannot plausibly be a major driver of U.S. drug spending or a major cause of cost shifting by drug manufacturers to make up for 340B discounts. Read the report and click here for an overview of the report’s findings, and click here for an infographic summarizing the findings. 

Financial Challenges Faced by 340B Disproportionate Share Hospitals In Treating Low-Income Patients

340B Health commissioned the research firm Dobson DaVanzo & Associates to evaluate the financial challenges faced by disproportionate share (DSH) hospitals participating in the 340B drug discount program due to their characteristics as safety net hospitals and their unique patient populations. Read the report.

Analysis of the Proportion of 340B DSH Hospital Services Delivered to Low-Income Oncology Drug Recipients Compared to Non-340B Providers

340B Health commissioned the research firm Dobson DaVanzo & Associates to evaluate whether 340B disproportionate share (DSH) hospitals treat a higher proportion of low income oncology drug recipients than do non 340B providers. Read more.

Analysis of 340B Disproportionate Share Hospital Services Delivered to Vulnerable Patient Populations
340B Health commissioned the research firm Dobson DaVanzo & Associates to conduct an analysis of hospitals using 2014 Medicare cost report data to determine the extent to which 340B disproportionate share (DSH) hospitals are targeting their services to vulnerable patient populations. Read more.

HRSA's Proposed Omnibus Guidance Would Jeopardize 340B Hospitals: Results from a Survey of 340B Health Members

The Health Resources and Services Administration’s 2015 proposed guidance on the 340B Drug Pricing Program may have intended to cut through previous confusion in the administration of the program, but a survey of 340B Hospitals indicates the proposed guidance would cause significant harm to hospitals that rely on 340B to provide critical care in their communities. Read the report.